References
- Public Health Agency of Canada. Hepatitis C: Get the facts. You can have it and not know it. Ottawa. 2012. http://www.phac-aspc.gc.ca/hepc/pubs/getfacts-informezvous/index-eng.php. Accessed February 5, 2015
- Public Health Agency of Canada. Hepatitis C Information for Health Professionals. Ottawa. 2008. http://www.phac-aspc.gc.ca/hepc/pubs/ihp-ips/index-eng.php. Accessed October 10, 2014
- Public Health Agency of Canada. Hepatitis C - Quick Facts. Ottawa. 2014. http://www.phac-aspc.gc.ca/hepc/index-eng.php. Accessed October 10, 2014
- Centers for Disease Control and Prevention. Hepatitis C FAQs for Health Professionals. Atlanta, GA. 2014. http://www.cdc.gov/hepatitis/hcv/hcvfaq.htm. Accessed October 10, 2014
- Planas R, Balleste B, Alvarez MA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol 2004;40:823-30
- Tsoulfas G, Goulis I, Giakoustidis D, et al. Hepatitis C and liver transplantation. Hippokratia 2009;13:211-15
- Hsu PC, Federico CA, Krajden M, et al. Health utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infection. J Gastroenterol Hepatol 2012;27:149-57
- Ly KN, Xing J, Klevens RM, et al. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012;156:271-8
- Public Health Agency of Canada. Hepatitis C in Canada: 2005–2010 Surveillance Report. Ottawa. 2011. http://publications.gc.ca/collections/collection_2012/aspc-phac/HP40-70-2012-eng.pdf. Accessed August 19, 2014
- Razavi H, Waked I, Sarrazin C, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today’s treatment paradigm. J Viral Hepat 2014;21(1 Suppl):34-59
- Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-74
- Chen J, Florian J, Carter W, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 2013;144:1450-5
- Martinot-Peignoux M, Stern C, Maylin S, et al. Twelve weeks post-treatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology 2010;51:1122-6
- U.S. Food and Drug Administration. Guidance for Industry. Chronic Hepatitis C Virus Infection: developing direct-acting antiviral drugs for treatment. Silver Spring, MD. 2013. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM225333.pdf. Accessed August 21, 2015
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014;60:392-420
- Bruggmann P, Berg T, Ovrehus AL, et al. Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat 2014;21(1 Suppl):5-33
- Chaudhary R, Tepper M, Eisaadany S, et al. Distribution of hepatitis C virus genotypes in Canada: Results from the LCDC Sentinel Health Unit Surveillance System. Can J Infect Dis 1999;10:53-6
- Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 2014;59:318-27
- Manns MP, von Hahn T. Novel therapies for hepatitis C - one pill fits all? Nat Rev Drug Discov 2013;12:595-610
- Tapper EB, Afdhal NH. Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3. J Viral Hepat 2013;20:669-77
- Krahn M, Wong JB, Heathcote J, et al. Estimating the prognosis of hepatitis C patients infected by transfusion in Canada between 1986 and 1990. Med Decis Mak 2004;24:20-9
- Krahn MD, John-Baptiste A, Yi Q, et al. Potential cost-effectiveness of a preventive hepatitis C vaccine in high risk and average risk populations in Canada. Vaccine 2005;23:1549-58
- El Saadany S, Coyle D, Giulivi A, et al. Economic burden of hepatitis C in Canada and the potential impact of prevention. Results from a disease model. Eur J Health Econ 2005;6:159-65
- Remis RS. Modelling the Incidence and Prevalence of Hepatitis C Infection and its Sequelae in Canada, 2007 [Internet]. Ottawa: Public Health Agency of Canada, 2009. http://www.phac-aspc.gc.ca/sti-its-surv-epi/model/pdf/model07-eng.pdf. Accessed August 19, 2015
- Werb D, Wood E, Kerr T, et al. Treatment costs of hepatitis C infection among injection drug users in Canada, 2006–2026. Int J Drug Policy 2011;22:70-6
- Dryden DM, Doucette K, Tandon P, et al. Granulocyte-colony stimulating factor for antiviral-associated neutropenia: systematic review and economic evaluation [Internet]. Ottawa: Canadian Agency for Drugs and Technologies in Health, 2008. http://www.cadth.ca/media/pdf/H0473_Granulocyte_Colony_Stimulating_Factor_tr_e.pdf. Accessed May 9, 2014
- Murphy G, Farah B, Wong W, et al. Direct Acting Antiviral Agents for Chronic Hepatitis C Genotype 1 [Internet]. Ottawa: Canadian Agency for Drugs and Technologies in Health, 2014. http://www.cadth.ca/media/pdf/TR0007_HepC_ScienceReport_e.pdf. Accessed January 24, 2015
- Brady B, Siebert U, Sroczynski G, et al. Pegylated interferon combined with ribavirin for chronic hepatitis C virus infection: an economic evaluation. Ottawa: Canadian Agency for Drugs and Technologies in Health, 2007
- Bunchorntavakul C, Reddy KR. Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther 2015;42:258-72
- Sarrazin C, Hezode C, Zeuzem S, et al. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012;56(1 Suppl):88-100
- Gentile I, Borgia F, Coppola N, et al. Daclatasvir: the first of a new class of drugs targeted against hepatitis C virus NS5A. Curr Med Chem 2014;21:1391-404
- Bristol-Myers Squibb Canada. Daklinza (daclatasvir) tablets, 30 and 60 mg. Product Monograph. Montreal, Quebec. 2015 [Internet]. http://webprod5.hc-sc.gc.ca/dpd-bdpp/info.do?code=92992&lang=eng. Accessed October2, 2015
- Gilead Sciences Canada Inc. Sovaldi (sofosbuvir) Product monograph. Mississauga, Ontario. 2015. http://webprod5.hc-sc.gc.ca/dpd-bdpp/item-iteme.do?pm-mp=00031317. Accessed August 9, 2015
- Merck Canada Inc. Pegetron Product Monograph. Kirkland, Quebec. 2013 [Internet]. http://webprod5.hc-sc.gc.ca/dpd-bdpp/item-iteme.do?pm-mp=00019617. Accessed January 28, 2015
- Hoffmann-La Roche Limited. Pegasys RBV (peginterferon alfa-2a and ribavirin) Product Monograph. Mississauga, Ontario. 2013 [Internet]. http://webprod5.hc-sc.gc.ca/dpd-bdpp/item-iteme.do?pm-mp=00021687. Accessed February 4, 2015
- Chung RT, Davis GL, Masur H, et al. Hepatitis C Guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with Hepatitis C Virus. Hepatology 2015;62(3):932-54
- European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 2015;63:199-236
- Martin NK, Vickerman P, Miners A, et al. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology 2012;55:49-57
- McEwan P, Ward T, Yuan Y, et al. The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States. Hepatology 2013;58:54-64
- Statistics Canada. Life Tables, Canada, Provinces and Territories, 2009 to 2011 [Internet]. Ottawa. 2013. http://www.statcan.gc.ca/pub/84-537-x/84-537-x2013005-eng.pdf. Accessed February 20, 2015
- Myers RP, Hilsden RJ, Lee SS. Historical features are poor predictors of liver fibrosis in Canadian patients with chronic hepatitis C. J Viral Hepat 2001;8:249-55
- Marotta P, Feinman S, Ghent C, et al. Final Results of the Canadian POWeR (Pegetron Prospective Optimal Weight-Based Dosing Response) Program. Sustained Virologic Response (SVR) to Weight-Based Peginterferon alfa-2b + Ribavirin in a Large, Mixed, Community and Academic Observational Study [Internet]. 58th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA. 2007. http://www.natap.org/2007/AASLD/AASLD_63.htm. Accessed March 14, 2014
- Nelson DR, Cooper JN, Lalezari JP, et al. All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase 3 Study. Hepatology 2015;61:1127-35
- Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014;370:1993-2001
- Swallow E, Song J, Yuan Y, et al. Comparative Efficacy and Tolerability of Daclatasvir + Sofosbuvir versus Sofosbuvir + Ribavirin for Hepatitis C Genotype 3: a Matching-Adjusted Indirect Comparison. European Association for the Study of the Liver. Vienna, Austria, 2015
- McLernon DJ, Dillon J, Donnan PT. Health-state utilities in liver disease: a systematic review. Med Decis Mak 2008;28:582-92
- Sullivan PW, Ghushchyan V. Preference-Based EQ-5D index scores for chronic conditions in the United States. Med Decis Mak 2006;26:410-20
- Del Rio RA, Post AB, Singer ME. Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy. Hepatology 2006;44:1598-606
- Krajden M, Kuo M, Zagorski B, et al. Health care costs associated with hepatitis C: a longitudinal cohort study. Can J Gastroenterol 2010;24:717-26
- Régie de l'assurance maladie du Québec. Liste des médicaments dernière mise à jour le 24 juillet 2015 [Internet]. Québec. 2014. https://www.prod.ramq.gouv.qc.ca/DPI/PO/Commun/PDF/Liste_Med/Liste_Med/liste_med_2015_07_24_fr.pdf. Accessed August 5, 2015
- Lachaine J, Vachon ML, Lambert-Obry V, et al. Costs Of Adverse Events Associated With Treatment Of Hepatitis C Virus Infection: An Analysis Using The Quebec Provincial Drug Reimbursement Program Database. Value Health 2014;17:A272
- Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies. Ottawa. 2006. https://www.cadth.ca/sites/default/files/pdf/186_EconomicGuidelines_e.pdf. Accessed August 7, 2015
- McEwan P, Ward T, Webster S, et al. Estimating the long-term clinical and economic outcomes of daclatasvir plus asunaprevir in difficult-to-Treat Japanese Patients chronically infected with Hepatitis C Genotype 1b. Value Health Reg Issues 2014;3:136-45
- McEwan P, Ward T, Chen C-J, et al. Estimating the incidence and prevalence of chronic Hepatitis C Infection in Taiwan Using Back Projection. Value Health Reg Issues 2014;3:5-11
- Townsend R, McEwan P, Kim R, et al. Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C. Value Health 2011;14:1068-77
- Salomon JA, Weinstein MC, Hammitt JK, et al. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003;290:228-37
- Van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584-93
- Chong CA, Gulamhussein A, Heathcote EJ, et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003;98:630-8
- Stedman CA. Current prospects for interferon-free treatment of hepatitis C in 2012. J Gastroenterol Hepatol 2013;28:38-45
- Federico CA, Hsu PC, Krajden M, et al. Patient time costs and out-of-pocket costs in hepatitis C. Liver Int 2012;32:815-25